



2019 Abstract Submission Guidelines and Procedures

Put a Spotlight on Your Innovative Research!

The 2019 CRS Annual Meeting offers an exceptional opportunity to share your research with an international audience in the discovery, development, and delivery continuum.

Scientific Session Format

Each scientific session will include invited speakers and several oral presentations that are selected from the submitted abstracts. A moderated discussion will follow the presentations.

Important Information to Know Before Submitting

Visa Information

It is the responsibility of the designated presenting author to determine their visa requirements to enter Spain. CRS strongly encourages the presenting author and all future attendees to review visa requirements and begin the visa application (as applicable) as soon as possible. **Registration fees will NOT be refunded due to inability to obtain a visa.**

Notification

- Acknowledgement of submission will be emailed to the presenting author as the primary contact.
- The designated presenting authors will be notified of the abstract status in **March 2019**. All future communications will be sent to the designated presenting author.
- The designated presenting author must register for the annual meeting and pay the fee by **May 1, 2019**.
- If the designated presenting author is not registered, the abstract will be withdrawn and will not be included in the annual meeting program.
- All expenses (e.g. conference registration, airfare, lodging, etc.) associated with the presentation of an abstract are the responsibility of the presenter.

View/Edit/Withdraw Your Abstract

- You may view, edit, or withdraw your abstract submission(s) by using the link provided in the confirmation email sent to the designated author.
- Abstract submissions may be edited or withdrawn until **January 31st, 2019** (11:59 p.m. Central Standard Time).

Abstract Preparation Checklist

- ✓ Abstract prepared and formatted as outlined in the Preparing for Abstract Submission section. Abstracts that are not properly prepared and formatted are subject to automatic rejection.
- ✓ Abstract has not been previously submitted for consideration in other competitions or meetings.
- ✓ Abstract (subject to acceptance) will be presented as placed (Oral Presentation or Poster Presentation) by the CRS Annual Meeting Program Committee.
- ✓ License is granted to CRS to publish the abstract (subject to acceptance) online. Designated presenting author registered for the CRS Annual Meeting and has paid the fee by **May 1, 2019**.

Abstract Submission

- If accepted, you will be part of the scientific program in the form of either an oral presentation or poster presentation.

- **Abstracts for the 2019 CRS Annual Meeting will be accepted until January 31st, 2019 (11:59 p.m. U.S. Central Standard Time).**
- All authors are expected to review this document prior to submitting.

Preparing for Abstract Submission

Author Information

- There is no limit to the number of abstracts an author may submit. If an abstract is accepted, the presenter must be one of the co-authors listed.
- Communications will only be sent to the designated presenting author

Session Categories Information

Abstracts will be accepted in the following categories; you will be asked to select a primary category and secondary category, followed by a focus group area of interest if applicable for your abstract.

1. Regenerative Medicine: Responsive Biomaterials and Cell Therapies
2. Neurological Disorders and Chronic Pain
3. Global Health and Neglected Diseases
4. Theranostics and Molecular Imaging
5. Hot Topics in Topical and Transdermal Delivery
6. Importance of a Rational Design: Carrier, Linker, Cargos
7. Delivery of Biomacromolecules (Proteins, Peptides And Antibodies)
8. Oral Delivery for Food and Nutraceuticals (C&DP)
9. New Approaches on Physico-Chemical Characterization, Scale-Up and Stability Measurements
10. Drug Delivery Against Antimicrobial Resistance
11. Micro-/Nano-Particle Delivery
12. Preclinical models of disease to foster clinical translation
13. Crossing Challenging Biological Barriers
14. Delivery in Cosmetics and Consumer Products (C&DP)
15. Focus Group Scientific Session: Gene Delivery and Editing (GDE)
16. Focus Group Scientific Session: Nanomedicine and Nanoscale Drug Delivery (NNDD)
17. Focus Group Scientific Session: Ocular Drug Delivery (OCDD)
18. Focus Group Scientific Session: Bioinspired and Biomimetic Drug Delivery (BBDD)
19. Focus Group Scientific Session: Transdermal and Mucosal Drug Delivery (TMD)
20. Focus Group Scientific Session: Oral Drug Delivery (OrDD)
21. Focus Group Scientific Session: Immuno Delivery (ID)

Format

- **Abstract body is limited to 400 words** (does not include title, authors, references or acknowledgements)
- **Up to two images uploaded** (optional)
- **In addition to the abstract, provide three (3) Learning Objectives** that at the conclusion of your presentation, meeting participants should be able to do. Use measurable action words and avoid using numbers, bullet points, asterisks, or any other special characters.

Examples of Measurable Action Words

Explain	Demonstrate	Analyze	Formulate
Discuss	Compare	Differentiate	Describe
Name	Assess	Evaluate	Identify
Design	Define	List	Develop

- **Abstract of original work – content should be structured into the following sections:**

Introduction - A brief statement about the purpose of the study and pertinent background.

Methods - The method(s) of study or data collection employed.

Results - A summary of study research including sufficient details to support your conclusions.

Conclusion/Implications - A statement explaining the significance of your work and the implications for further research, practice and/or policy.

Acknowledgements: In one line, state the supporting grant number and agency name. (optional)

References: List Author Name(s). Journal Name. Year. Page Number(s).

Presenter Biography: A brief, 2-3 sentences about the presenting author.

- **Abstract must be written in clear English.**
- If not all data (example: active compound used) can be disclosed due to confidentiality, the abstract will not be rejected immediately; however, the reviewers will decide whether or not it contains enough interesting insights for acceptance.

Terms & Conditions

*If the abstract is accepted, I agree that the designated presenting author will present the abstract at the 2019 Controlled Release Society Annual Meeting, July 21-24, 2019, Valencia, Spain and will register and pay the registration fee by **May 1st, 2019**. I confirm that this is at least in part original work and that the text, figures, and tables included in the abstract have not been published previously. I and any contributing authors, as sole proprietors of the abstract, agree to transfer copyright of the abstract to the Controlled Release Society. By agreeing, I accept this copyright transfer. I understand that failure to accept the copyright transfer will result in the immediate cancellation of my abstract submission.*

Criteria for Acceptance

- Abstract has not been previously submitted for consideration in other competitions or meetings.
- The criterion for acceptance of presentation at the CRS Annual Meeting and Exposition is based on an anonymous peer-review process. The author must obtain the necessary permissions prior to submission of the abstract.
- The CRS Annual Meeting Program Committee reserves the right to evaluate, accept, or reject any submitted abstract. The committee will determine the status (accept or reject) of all submitted abstracts and the placement (oral or poster presentation) of all accepted abstracts. The committee may also switch abstracts to any topic category based on their evaluation and organization requirements.
- **Presenting author to register by the *May 1st, 2019* presenter registration deadline to avoid having the abstract withdrawn from the program.**

Presenter Registration Deadline

- Notification of acceptance will be emailed in March to the presenting author only.
- **If the abstract is accepted, the designated presenting author must register and pay the fee by *May 1st, 2019*, for the 2019 CRS Annual Meeting, July 21-24, 2019, in Valencia, Spain, and must agree to present the abstract at the annual meeting.**
- **It is the responsibility of the presenting author to register by the presenter registration deadline. If the designated presenting author is NOT registered by the *May 1st, 2019* deadline, the abstract will be withdrawn and will not be included in the program or in the 2019 CRS Annual Meeting online abstract library.** If you do not present your abstract or if your poster is not displayed during the designated poster times your abstract will be removed from the online abstract library.

Review Procedure

All abstracts submitted to the CRS Annual Meeting will go through a rigorous review procedure to maintain the highest scientific quality of the meeting. The abstract will be evaluated by the CRS Annual Meeting Program Committee and will be assigned a rank order based on its scientific content. Some abstracts will be selected for oral presentations during regular scientific sessions. Abstract will be rejected if it does not comply with minimum submission instructions, does not follow the proper format, and/or does not include all required fields.

Submitted abstracts must meet the following minimum requirements:

- Significant and original contribution within the scope of the Controlled Release Society.
- Abstract submitted by the deadline.
- Written in clear English.
- Few syntax/spelling mistakes.
- Sufficient data presented, adequately analyzed and discussed with appropriate conclusions supported by the data. If not all data (example: active compound used) can be disclosed due to confidentiality, the abstract will not be rejected immediately; however, the reviewers will decide whether or not it contains enough interesting insights for acceptance.
- Meets format guidelines.

Abstract Permission

Submission Permissions

Submitting author must obtain the necessary permissions for research prior to abstract submission. The Controlled Release Society does not assume any liability or responsibility for publication of any submitted abstracts.

Copyright Assignment

Submitting author confirms that the abstract is an original work and has not been previously published. The submitter and any contributing authors, as sole proprietors of the abstract, agree to transfer copyright of the abstract to the Controlled Release Society. By agreeing, the submitter accepts the copyright transfer. Failure to accept the copyright transfer will result in the immediate cancellation of the abstract submission.

Copyright Permissions

Publication of tables, charts, and graphs projected onto screens or posted at the annual meeting by anyone other than an author or presenter is prohibited unless a release has been requested and received in writing from an author or presenter.

Agreement to Present

Designated presenting author must agree to present their abstract (subject to acceptance) at the CRS Annual Meeting and Exposition.

Agreement to Register

Designated presenting author of the abstract (subject to acceptance) must register for the annual meeting and pay the fee by May 1, 2019. If the designated presenting author is not registered by the presenter registration deadline, the abstract will be withdrawn and will not be included in the program guide or the online abstract library.

Abstract Sample

The learning objectives, title, and authors are NOT included in the abstract body 400 word count.

MicroCT Imaging of Non-Small Cell Lung Cancer (NSCLC) by Targeting Angiogenic Tumor Vasculature

Presenting Author: Michael Dunne, University of Toronto, Canada

Co-Authors: Jinzi Zheng, University of Toronto; David Jaffray, University of Toronto, Canada; Princess Margaret Hospital, Canada; Christine Allen, University of Toronto, Canada

Abstract Body – 400 word count *(you will cut and paste this into the text box in the abstract portal)*

Introduction: Angiogenesis is required to supply malignant tumors with oxygen and nutrients. This research seeks to develop a contrast agent capable of targeting angiogenic vasculature, allowing for early tumor detection and characterization. Peptides containing the asparagine-glycine-arginine (NGR) amino acid sequence selectively target the isoform of the matrix metalloprotease aminopeptidase N (APN) (a prognostic factor in various solid tumors including NSCLC) expressed on endothelial cells lining tumor vasculature. Previous studies have demonstrated NGR-targeting can significantly increase tumor accumulation and therapeutic efficacy of antineoplastic drugs. The actively targeted contrast agent developed herein allows for tumor characterization and informs on the biodistribution of targeted liposome-based therapeutics.

Methods: A hexapeptide containing the NGR motif was conjugated to maleimide-functionalized PEG₂₀₀₀-DSPE and transferred into preformed sterically stabilized liposomes containing iohexol (NGR-liposomes). Characterization of the liposomes included measuring size and stability by dynamic light scattering. *In vitro* cell association assays were performed at 4°C by incubating liposomes with cancer cells expressing APN. Pharmacokinetics and biodistribution were examined in mice bearing subcutaneous human NSCLC tumors by repeated microCT imaging following intravenous administration. Intratumoral distribution was examined by comparing proximity of liposomes to vasculature in tumor sections using fluorescence microscopy.

Results: The conjugation efficiency of NGR to maleimide-PEG₂₀₀₀-DSPE was determined to be >80% using ultra-performance liquid chromatography. Both targeted and non-targeted liposomes were ~85nm in diameter with a unimodal size distribution. NGR-liposomes demonstrated a statistically significant increase in cellular association. CT images showed increased tumor accumulation of NGR-liposomes and differences in blood pool clearance.

Conclusion: This is the first *in vivo* evaluation of a long-circulating APN-targeted contrast agent. The significant tumor accumulation of this molecular targeted agent suggests potential applications in disease staging and therapy planning.

Acknowledgements: In one line, state the supporting grant number and agency name (optional)

References (up to three): List Author Name(s). Journal Name. Year. Page Number(s).

Example of Learning Objectives

These are NOT included in the abstract body word count.

Differentiate between tumor vasculature and normal tissue vasculature.

Explain the strategies for targeting tumor vasculature.

Identify several cell surface receptors overexpressed on tumor vasculature.

Evaluate the increased nanomedicine accumulation in tumors resulting from active targeting of APN.